BP003316: Human NKp80/CLEC5C Protein with the N-hFc Tag

Source: The recombinant Human NKp80/CLEC5C Protein, (amino acids Leu60-Tyr231) fused with a hFc tag at the N-terminus, was produced in HEK 293 cells.
Activity:
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.

BP003220: Biotinylated Human Peptide Ready HLA-A*24:02&B2M Monomer-Protein with the C-His-Avi Tag

Source: The recombinant Biotinylated Human Peptide Ready HLA-A*24:02&B2M Monomer-Protein, (amino acids Gly25-Thr305(HLA-A*24:02) & Ile21-Met119(B2M)) fused with a His-Avi tag at the C-terminus, was produced in HEK 293 cells.
Activity: Immobilized recombinant Biotinylated Human Peptide Ready HLA-A*24:02&B2M Monomer protein with the C-His-Avi tag at 0.5 ug/ml (100 ul/well) on the streptavidin precoated plate (5 ug/ml). Dose response curve for the recombinant Anti-HLA class I (W6/32) Antibody protein with the C-hFc tag with the EC50 of 4.1 ng/ml determined by ELISA.
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.

BP003221: Human Peptide Ready HLA-A*24:02&B2M Monomer Protein with the C-His-Avi Tag

Source: The recombinant Human Peptide Ready HLA-A*24:02&B2M Monomer Protein, (amino acids Gly25-Thr305(HLA-A*24:02) & Ile21-Met119(B2M)) fused with a His-Avi tag at the C-terminus, was produced in HEK 293 cells.
Activity: Immobilized recombinant Human Peptide Ready HLA-A*24:02&B2M Monomer protein with the C-His-Avi tag at 0.5 ug/ml (100 ul/well) on the plate. Dose response curve for the recombinant Anti-HLA class I (W6/32) Antibody protein with the C-hFc tag with the EC50 of 3.1 ng/ml determined by ELISA.
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.

BP003291: Human Peptide Ready HLA-G&B2M Monomer Protein with the C-His-Avi Tag

Source: The recombinant Human Peptide Ready HLA-G&B2M Monomer Protein, (amino acids Gly25-Thr305(HLA-G) & Ile21-Met119(B2M)) fused with a His-Avi tag at the C-terminus, was produced in HEK 293 cells.
Activity:
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.

BP003292: Biotinylated Human Peptide Ready HLA-A*03:01&B2M Monomer Protein with the C-His-Avi Tag

Source: The recombinant Biotinylated Human Peptide Ready HLA-A*03:01&B2M Monomer Protein, (amino acids Gly25-Thr305(HLA-A*03:01) & Ile21-Met119(B2M)) fused with a His-Avi tag at the C-terminus, was produced in HEK 293 cells.
Activity: Immobilized recombinant Biotinylated Human Peptide Ready HLA-A*03:01&B2M Monomer protein with the C-His-Avi tag at 1 ug/ml (100 ul/well) on the streptavidin precoated plate(5 ug/ml). Dose response curve for the recombinant Anti-HLA class I (W6/32) Antibody protein with the C-hFc tag with the EC50 of 4.2 ng/ml determined by ELISA.
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.

BP003297: Biotinylated Human Peptide Ready HLA-A*02:01&B2M Monomer Protein with the C-His-Avi Tag

Source: The recombinant Biotinylated Human Peptide Ready HLA-A*02:01&B2M Monomer Protein, (amino acids Gly25-Thr305(HLA-A*02:01) & Ile21-Met119(B2M)) fused with a His-Avi tag at the C-terminus, was produced in HEK 293 cells.
Activity: Immobilized recombinant Biotinylated Human Peptide Ready HLA-A*02:01&B2M Monomer protein with the C-His-Avi tag at 1 ug/ml (100 ul/well) on the streptavidin precoated plate (5 ug/ml). Dose response curve for the recombinant Anti-HLA class I (W6/32) Antibody protein with the C-hFc tag with the EC50 of 2.7 ng/ml determined by ELISA.
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.

MB112: Proteinase K Solution, PCR Grade

Proteinase K is commonly used for protein digestion, DNA extraction, RNA purification, direct PCR, and genotyping. The recombinant proteinase K enzyme is a mutant to the native protease, which gains higher specific activity and yield as well as wider pH and temperature range . The large scale recombinant enzyme production has advantage in lot-to-lot consistency, superior purity and cost-efficiency. DNA-free nature of recombinant Proteinase K made it well-suited in isolating PCR and RT-PCR templates.
High purity: Each lot of the recombinant proteinase K solution (molecular biology grade, PCR grade, NGS grade, chip grade, and RNA grade) was tested to ensure the absence of DNases and RNases, and free of DNA.
The cheapest proteinase K solution in the market.
Specific activity:  ≥ 780 units/ml.

BP4200: Recombinant Dr. Nuclease

Source: E. coli-derived.
Specific activity: ≥1.1 x 10^6 U/mg. One unit of Dr. Nuclease is defined as the amount of enzyme required to produce a change in absorbance at 260 nm of 1.0 in the time of 30 minutes, under optimum conditions with excess substrate.
Purity: ≥95% by SDS-PAGE and ≥99% by SEC-HPLC. It does not contain any antimicrobial preservatives or protein stabilizers except glycerol (of synthetic origin).

BP4200-GMP: Recombinant Dr. Nuclease, GMP Grade

Source: E. coli-derived.
Predicted molecular mass: ~28 kDa.
Specific activity: ≥1.1 x 10^6 U/mg. One unit of Dr. Nuclease is defined as the amount of enzyme required to produce a change in absorbance at 260 nm of 1.0 in the time of 30 minutes, under optimum conditions with excess substrate.
Purity: ≥95% by SDS-PAGE and ≥99% by SEC-HPLC. It does not contain any antimicrobial preservatives or protein stabilizers except glycerol (of synthetic origin).
Formulation: 0.2 μM filtered solution (250 units/ul) of 20 mM Tris-HCl, pH 8.0, 2 mM MgCl2, 2 mM NaCl, 50% Glycerol.
Endotoxin level: ≤0.01 EU/1000 units following 2020 ChP 1143 USP <85>.
Protease activity: No detectable protease activity using casein as substrate.
Residual host cell protein: ≤10.0 ppm by ELISA.
Mycoplasma: negative by qPCR method.
Bioburden: negative following 2020 ChP 1105 USP <61>.
Residual heavy metal: ≤10.0 ppm following 2020 ChP 0821 USP <32>.

BP4200: Recombinant Dr. Nuclease

Source: E. coli-derived.
Specific activity: ≥1.1 x 10^6 U/mg. One unit of Dr. Nuclease is defined as the amount of enzyme required to produce a change in absorbance at 260 nm of 1.0 in the time of 30 minutes, under optimum conditions with excess substrate.
Purity: ≥95% by SDS-PAGE and ≥99% by SEC-HPLC. It does not contain any antimicrobial preservatives or protein stabilizers except glycerol (of synthetic origin).

BP4200-GMP: Recombinant Dr. Nuclease, GMP Grade

Source: E. coli-derived.
Predicted molecular mass: ~28 kDa.
Specific activity: ≥1.1 x 10^6 U/mg. One unit of Dr. Nuclease is defined as the amount of enzyme required to produce a change in absorbance at 260 nm of 1.0 in the time of 30 minutes, under optimum conditions with excess substrate.
Purity: ≥95% by SDS-PAGE and ≥99% by SEC-HPLC. It does not contain any antimicrobial preservatives or protein stabilizers except glycerol (of synthetic origin).
Formulation: 0.2 μM filtered solution (250 units/ul) of 20 mM Tris-HCl, pH 8.0, 2 mM MgCl2, 2 mM NaCl, 50% Glycerol.
Endotoxin level: ≤0.01 EU/1000 units following 2020 ChP 1143 USP <85>.
Protease activity: No detectable protease activity using casein as substrate.
Residual host cell protein: ≤10.0 ppm by ELISA.
Mycoplasma: negative by qPCR method.
Bioburden: negative following 2020 ChP 1105 USP <61>.
Residual heavy metal: ≤10.0 ppm following 2020 ChP 0821 USP <32>.